Back to NVSView full pipeline
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
0 competitors in Chronic Myelogenous Leukemia - Chronic Phase
View Full LandscapeDrug Information
Target Indication
Chronic Myelogenous Leukemia - Chronic Phase
Clinical Trial
NCT04666259Last updated: 2/9/2026
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Related Pipeline
Peg-alpha interferon (Peg-Intron)Phase 3
Leukemia, Myeloid, Chronic
cyclosporin + mycophenolate mofetilPhase 3
Kidney Failure
Imatinib Mesylate (Gleevec)Phase 3
Idiopathic Pulmonary Fibrosis
GP2017 (adalimumab biosimilar)Phase 3
Ankylosing Spondylitis
Nilotinib (Tasigna ®)Phase 3
Chronic Myeloid Leukemia
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts